Pacbio is in it for the long run
The sequencing sector is changing fast, but Pacbio believes its technology can hold out against its rivals.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
Illumina sees the light – or thinks it does
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Antitrust watchdog plunges Illumina’s megamerger into darkness
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Illumina bets on Pacific, not nanopores
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.